The GLP-1 discovery and development of its agonists have revolutionized biomedical research focusing on metabolic disorders, such as obesity, T2DM, atherosclerosis and cardiovascular diseases (CVDs) and pharmaceutical industrial revenue. The gene discussed is GCG; the disease is obesity disorder.